Analysis of the Frequency and Outcomes of Transformed Nodular Lymphocyte-Predominant Hodgkin Lymphoma in the United States: A Population-Based Study - Report - MDSpire
Advertisement
Analysis of the Frequency and Outcomes of Transformed Nodular Lymphocyte-Predominant Hodgkin Lymphoma in the United States: A Population-Based Study
Clinical Report: Frequency and Outcomes of Transformed NLPHL in the US
Overview
This population-based study analyzes the incidence and survival outcomes of transformed nodular lymphocyte-predominant Hodgkin lymphoma (t-NLPHL) compared to non-transformed NLPHL and de novo diffuse large B-cell lymphoma (DLBCL) diagnosed between 2010 and 2022. The findings indicate a cumulative incidence of histologic transformation of 2.59% and highlight poorer survival outcomes for patients with t-NLPHL.
Background
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an indolent B-cell lymphoma with a generally favorable prognosis. However, a subset of patients may experience histologic transformation to diffuse large B-cell lymphoma (DLBCL), which is associated with adverse outcomes. Understanding the incidence and clinical implications of this transformation is crucial for improving patient management and outcomes.
Data Highlights
Outcome
Non-transformed NLPHL
Transformed NLPHL
De novo DLBCL
5-year Relative Survival (RS)
97% (95% CI, 96–98)
88% (95% CI, 73–95)
67% (95% CI, 67–68)
5-year Overall Survival (OS)
93% (95% CI, 92–94)
86% (95% CI, 72–93)
N/A
5-year Lymphoma-specific Survival (LSS)
97% (95% CI, 95–97)
89% (95% CI, 76–95)
N/A
5-year Cumulative Incidence of Death from Lymphoma (CIF)
3% (95% CI, 3–5)
11% (95% CI, 5–24)
N/A
Key Findings
The cumulative incidence of histologic transformation in NLPHL was found to be 2.59% over a median follow-up of 5.58 years.
Patients with t-NLPHL had a median age of 52 years, compared to 66 years for those with de novo DLBCL.
5-year relative survival rates were significantly lower for patients with t-NLPHL (88%) compared to non-transformed NLPHL (97%).
Transformed NLPHL patients had a higher likelihood of advanced stage disease at diagnosis (59% vs 54% for DLBCL).
Despite poorer outcomes compared to non-transformed NLPHL, t-NLPHL patients had better survival rates than those with de novo DLBCL.
Clinical Implications
The findings underscore the importance of monitoring patients with NLPHL for signs of histologic transformation, as this significantly impacts survival outcomes. Clinicians should consider aggressive management strategies, such as chemotherapy and radiation, for patients diagnosed with t-NLPHL, following DLBCL treatment protocols.
Conclusion
This study highlights the relatively low incidence of histologic transformation in NLPHL and the associated adverse survival outcomes, emphasizing the need for careful monitoring and management of affected patients to improve their prognosis.
